Linked Life Data

15927903

Source:http://linkedlifedata.com/resource/pubmed/id/15927903

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2005-6-1
pubmed:abstractText
Using data from a published clinical trial, our objectives were to compare the cost advantage of voriconazole over amphotericin B deoxycholate (AmBd) for primary treatment of invasive aspergillosis and to determine the financial impact the findings would have in a real-world clinical setting.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0277-0008
pubmed:author
pubmed:issnType
Print
pubmed:volume
25
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
839-46
pubmed:dateRevised
2009-11-3
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Cost advantage of voriconazole over amphotericin B deoxycholate for primary treatment of invasive aspergillosis.
pubmed:affiliation
Department of Pharmacy, University of Texas Health Science Center at San Antonio, University Health System, San Antonio, Texas, USA. james.lewis@uhs-sa.com
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't